Fractal's TMT weakness story shifts from client issues to AI capex reallocation
In three months, the narrative flipped from contained client problems to a broad opex-to-capex shift, without reconciling the earlier guidance or explaining the delayed recovery.
What's new
- Q1 FY27 revenue ₹913 cr, up 20% YoY, but TMT declined 22% YoY and dragged consolidated growth.
- HLS grew 69% YoY, becoming the second-largest vertical; BFSI grew 36% and CPG/retail 19%.
- Adjusted EBITDA margin improved to 16.8%; net income jumped 92% to ₹72 cr.
- Cure.ai revenue surged 160% YoY to ₹24 cr, but Fractal's share of loss rose to ₹23 cr from ₹22 cr.
Themes from the call
Demand
AI spending is moving into core budgets, but TMT clients are reallocating opex to AI capex, pressuring near-term revenue.
Margins
Adjusted EBITDA margin improved to 16.8% despite TMT headwinds, aided by pricing and mix shift.
Capital allocation
R&D spend could rise to 10% of revenue as gross margins expand; no major acquisitions flagged.
Guidance watch
- TMT revenue expected to show healthy sequential growth in Q2 FY27, driven by new deals already in the bag (directional only).
- Outcome/output/license revenue mix to reach 60% over the next few quarters (accelerated from previous two-to-three-year timeline).
- License revenue (currently 3%) expected to move above 3%; Kojentic revenue to be reported separately from next quarter.
- FY27 full-year growth expected to accelerate as new go-to-market structure settles; no quantitative target provided.
Risk flags
- The TMT narrative flip from client-specific to industry-wide suggests the headwind may be structural, not transient.
- The outcome/output/license mix timeline acceleration was not reconciled with the modest 2pp improvement (40% to 42%).
- Cure.ai losses grew despite management's prior expectation of no additional losses; profitability timeline unclear.
- CFO departure creates a leadership gap; successor not yet appointed.
Key quotes
-
"We expect these client-specific growth issues to have worked themselves out through this year, and therefore, we expect to do better in the TMT vertical in the next few quarters."
— Srikant Velamakanni, Co-founder & CEO, May 2026 call -
"There is a lot of opex pressure when capex has gone up by this much. Therefore, you are seeing big adjustments taking place in the TMT industry..."
— Srikant Velamakanni, Co-founder & CEO, July 2026 call -
"Five of our largest deals this quarter came through a partner. A year ago, AI was just an experimentation budget spent in pockets. Today, it is the core budget."
— Srikant Velamakanni, prepared remarks
The brief
Fractal's Q1 FY27 results carried a strong underlying beat—20% revenue growth, a 16.8% EBITDA margin, and zero churn. But the story that mattered changed between calls. In May, management told investors that TMT weakness was client-specific and would resolve in 'the next few quarters.' In July, that explanation was gone. Instead, the call described a broad industry shift from opex to AI capex, with no bridge between the two narratives. The same happened with the outcome/output/license mix target: the 60% goal was accelerated from two-to-three years to 'the next few quarters,' even though the actual mix inched from 40% to just 42%. And on Cure.ai, management had promised no additional losses this year; the share of loss actually increased. The underlying business is strong—HLS grew 69%, NRR hit 117%, and AI budgets are moving into core spend. But the credibility on TMT guidance, the mix timeline, and the associate loss has taken a hit. The next test is whether the new TMT narrative of a structural reallocation holds or whether the earlier client-specific view returns.
Fractal's numbers are solid, but the shifting explanations on TMT, mix targets and associate losses create a new layer of execution risk.